[03 October 2012]
Products Affected - Description
Methergine injection, Novartis
0.2 mg/mL, 1 mL vial (NDC 00078-0053-03) - discontinued
Methergine tablets, Novartis
0.2 mg tablets, 100 count (NDC 00078-0054-05) - discontinued
Reason for the Shortage
- Novartis discontinued both Methergine injection and tablets in early 2012.
- Akorn cannot provide a reason for the shortage of methylergonovine maleate injection.
Methylergonovine maleate injection, Akorn
0.2 mg/mL, 1 mL vial (NDC 17478-0501-01)
Methylergonovine maleate injection, American Regent
0.2 mg/mL, 1 mL vial (NDC 00517-0740-20)
Methylergonovine maleate tablets, Gavis Pharmaceuticals
0.2 mg tablets, 28 count (NDC 43386-0140-28)
0.2 mg tablets, 100 count (NDC 43386-0140-01)
Estimated Resupply Dates
All presentations are available.
October 3, 2012; August 3, 2012; June 6, 2012; June 4, 2012; May 22, 2012; April 17, 2012, University of Utah, Drug Information Service. Copyright 2012, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins